Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACD855
- Development stage
- Discontinued
- Lead developer
- AlzeCure Pharma
- Modality
- Small Molecules
- Administration
- Oral, Ophthalmic
01
Overview
ACD855 is a small molecule positive allosteric modulator (PAM) of the tropomyosin receptor kinases TrkA and TrkB, originally developed by AlzeCure Pharma for the treatment of cognitive and psychiatric disorders, including Alzheimer's disease and depression. The compound works by potentiating neurotrophin signaling, specifically involving nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), to enhance neuronal function and cognitive performance. Chemically, ACD855 is identical to the veterinary antiparasitic agent ponazuril. Although it demonstrated robust cognitive effects in preclinical models and was found to be safe in Phase I clinical trials, its development for systemic indications was terminated in 2019 due to an unexpectedly long half-life in humans. Following this termination, AlzeCure redirected the compound toward local administration for ocular indications, while its backup candidate, ACD856, became the primary lead for oral cognitive therapy.
- Other names
- ponazuril
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on ACD855.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACD855.